Anto Biosciences
A Foundation Model for Microbial Communities.
About Anto Biosciences
Anto is building a foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving the hidden root cause of most drug failures.
Founded by Arvid (Broad Institute of MIT and Harvard; Nature-published researcher who pioneered quality-aware, goal-directed sparsification) and David (Harvard Medical School Gastroenterology, J&J), second-time founders who published the breakthrough at leading machine learning AI conferences and Nature.
Company details
Funding
Total raised
$600K
Last stage
Seed
Investors
Founders
Arvid E. Gollwitzer
Researcher at the Broad Institute of MIT and Harvard and Langer/Traverso Labs at MIT. Nature-published researcher who pioneered quality-aware, goal-directed sparsification for microbiome data. Studied at ETH Zurich, MIT, and Harvard Medical School. Second-time founder (previously NextGuide).
LinkedInDavid de Gruijl
Co-founder @ Anto. Formerly Janssen Pharmaceuticals, ETH Zurich and Gastroenterology Dept. of BWH, Harvard Medical School.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.
